Irvine, CA – Kiel, May 11, 2010 – Proteo, Inc. (OTCBB: PTEO; Frankfurter Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today that new preclinical data on Proteo's drug substance Elafin will be presented on May 17 at the Annual International Conference of the American Thoracic Society in New Orleans. This Conference is the largest US meeting for healthcare professionals in pulmonary, critical care, and sleep medicine.
Scientists from the Vera Moulton Wall Center for Pulmonary Vascular Disease at the Stanford University School of Medicine studying this disease and its treatments are communicating their latest results. They are presenting a poster with the title »Adverse Pulmonary Effects of Mechanical Ventilation in Newborn Mice Are Prevented or Attenuated by the Serine Elastase Inhibitor Elafin.«
Preterm babies who require breathing support often develop chronic lung disease which represents a considerable health risk with long term consequences, notably increased susceptibility to recurrent childhood respiratory ailments, and chronic lung disease in later life, such as bronchial asthma and pulmonary emphysema. It is thought that ventilation-induced inflammation in the lungs may be part of the cause.
The research was performed on a preclinical animal model for neonatal chronic lung disease. The data show that in newborn mice mechanical ventilation with oxygen-rich gas stimulates inflammation, causing significant damage to the lungs such as elastic fiber degradation, pulmonary cell death and activation of inflammatory mediators. The resulting pulmonary injury also impairs lung growth. Treatment with Elafin during mechanical ventilation largely prevented this inflammation.
The principal investigator at Stanford Dr. Richard Bland, specialist in newborn medicine and neonatal lung disease: »The results raise hopes that Elafin could be administered to infants to alleviate or prevent neonatal chronic lung disease and its long-term consequences.«
Proteo's drug substance Elafin is a natural human antagonist of elastase and proteinase-3, two potent tissue destroying enzymes, both of which participate in the inflammatory mechanism of a variety of diseases. Elafin's ability to block these inflammation promoting enzymes makes it a promising drug candidate for the treatment of inflammatory lung diseases and severe reperfusion injury. The excellent tolerability of intravenously administered recombinant Elafin was demonstrated convincingly in a Phase I clinical trial. The results of a Phase II clinical trial for the treatment of postoperative inflammatory reactions of esophagus carcinoma are currently being evaluated. Proteo's licensing and development partner, Minapharm Pharmaceuticals SAE, has initiated a further Phase II clinical trial on the use of Elafin in kidney transplantation patients. This trial is concerned with the prevention of acute organ rejection and chronic graft injury (allograft nephropathy) and will be conducted at the University of Cairo. As a further cooperation partner, the University of Edinburgh is planning a clinical trial to test Elafin in the context of bypass surgery after a heart attack.
The company researches, develops and markets compounds for biological and medical research as well as for use as pharmaceuticals. The main focus is on anti-inflammatory drugs, in particular on the human elastase inhibitor Elafin. Proteo intends to out-license selected indications and to establish international strategic alliances in order to open up new fields of application and for marketing.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward looking statements and risks and uncertainties involved are further qualified by other factors including, but not limited to those set forth in the company's Form 10-K filing and other filings with the United States Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
Telephone: +49 431 8888-462
Fax: +49 431 8888-463